Acquisition of Surgical Biologics, LLC (Details) (USD $)	0 Months Ended	1 Months Ended		12 Months Ended
	Jan. 05, 2011	Jul. 31, 2012	Apr. 30, 2012	Dec. 31, 2012		Dec. 31, 2011
Business Acquisition [Line Items]
Cash Paid	$ 500,000
Convertible secured promissory note	1,250,000
Convertible Promissory Notes, interest rate (in hundredths)	4.00%
Common Stock valued	7,087,500	893,267
Common Stock issued (in shares)	5,250,000		2,632,576
Value of shares issued (in dollars per share)	$ 1.35
Common stock held in escrow (in shares)	525,000
Convertible Promissory Note, conversion price (in dollars per share)				$ 1.00
Convertible promissory note, stock price trigger (in dollars per share)				$ 1.75
Number of consecutive trading days				20 days
Maturity period of convertible promissory notes				18 months
Repayments of Convertible Debt		177,000		427,126		0
Accrued Earn Out [Roll Forward]
Beginning balance at beginning period				7,410,503		0
Valuation at acquisition date	7,404,700					0
Remeasurement adjustments				1,567,050		5,803
Common stock issued for earn-out liability				(3,185,223)		0
Ending balance at ending period				5,792,330		7,410,503
Actual purchase price allocated [Abstract]
Value of 5,250,000 shares issued at $1.35 per share	7,087,500
Cash paid at closing	350,000
Cash retained for working capital	150,000
Assumed Debt	182,777
Convertible Secured Promissory Note	1,250,000
Fair value of earn-out	7,404,700
Total fair value of purchase price	16,424,977
Tangible assets [Abstract]
Debt-free working capital	671,880
Other assets, net	385
Property, plant and equipment	72,866
Tangible assets purchased	745,131
Acquired Indefinite-lived Intangible Assets [Line Items]
Total acquired intangible assets	12,497,000
Goodwill	3,182,846
Total Assets Purchased	16,424,977
Working capital [Abstract]
Cash	33,583
Prepaid Expenses	2,738
Accounts Receivable	181,087
License Receivable	340,000
Inventory	347,106
Accounts payable and accrued expenses	(196,101)
Deferred rent and customer deposits	(36,533)
Debt-free working capital	671,880
Current portion of debt	(62,590)
Long-term debt	(21,187)
Line of credit	(99,000)
Net working capital	489,103
Deposits	16,582
Deferred rent (non-current)	(16,197)
Deposits net of deferred rent (non-current)	385
Trade names and trademarks [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired intangible asset	1,008,000
Estimated useful life (in years)				indefinite
In-process research and development - liquid [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired intangible asset	2,160,000
Estimated useful life (in years)				indefinite	[1]
In-process research and development - other [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired intangible asset	25,000
Estimated useful life (in years)				indefinite
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets	3,520,000
Estimated useful life (in years)				14 years
Supplier Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets	241,000
Estimated useful life (in years)				14 years
Patents and Know-How [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets	5,530,000
Estimated useful life (in years)				14 years
Licenses and Permits [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired intangible assets	$ 13,000
Estimated useful life (in years)				3 years

[1] AmnioFix injectable was launched in 2012 with amortization recorded over its expected useful life.